To assess the role of CMR in the treatment of true chronic total occlusions (CTO) with percutaneous coronary intervention (PCI) and drug eluting stent implantation.
Introduction
Successful PCI for CTO may confer an improved prognosis and a reduction in major adverse cardiac events. However most trials have included occlusions of short duration (less than 4 weeks). In this study we assessed the impact of PCI on LV function in patients with true CTOs (TIMI flow grade 0 and greater than 12 weeks duration) using serial CMR imaging as well as the predictive value of late gadolinium enhancement when performed prior to revascularization.
Anzeige
Methods
Thirty patents referred for PCI to a single vessel CTO underwent CMR examination prior to and six months after PCI. Technical success was defined as recanalization of the occluded vessel and DES implantation with a final residual diameter stenosis <30%. LV function and infarct size were assessed using a 1.5T GE MRI system. Segmental wall thickening (SWT) was measured within the perfusion territory of the CTO using the 16-segment model and segments were dysfunctional if the SWT was ≤45%. The transmural extent of infarction (TEI) was calculated by dividing the hyperenhanced area by the total area x 100; a score of ≤25% were considered viable.
Results
Technical success was achieved in 19 of the 30 patients (63%). CTO duration was greater in patients with failed revascularization but other baseline demographics were well matched between groups (Table 1). PCI-CTO success resulted in a significant increase in LVEF when compared to both baseline (50 ± 13 vs 54 ± 11; P < 0.01) and with PCI-CTO failure (11.8 ± 19.8 vs -2.3 ± 5.1, p < 0.01, Figure 1). In dysfunctional but viable segments only PCI success conferred a significant improvement in SWT compared to baseline (26 ± 6 vs 40 ± 10; P < 0.001, Figure 2). There were no episodes of major adverse cardiac events in either group at 21 months follow up.
Table 1
Baseline demographics
Total (n=30)
CTO-PCI success (n=19)
CTO-PCI failure (n=11)
P-value
Age/ years
62.2 ± 10.2
62.4 ± 9.8
61.8 ± 11.4
0.89
Male,n (%)
25 (83)
14 (74)
11 (100)
0.13
CCSA anginal class
2.13 ± 0.68
2.21 ± 0.63
2.0 ± 0.77
0.42
LVEF/ %
53.0 ± 11.6
50.3 ± 12.6
57.6 ± 8.1
0.09
CTO duration, months
36.9 ± 70.8
12.6 ± 26.4
78.8 ± 101.1
0.01
Vessel, n (%)
0.35
RCA
16 (53)
9 (47)
7 (64)
LAD
11 (37)
7 (37)
4 (36)
LCx
3 (10)
3 (16)
0
Prior MI, n (%)
17 (59)
11 (58)
6 (56)
0.61
Diabetes mellitus, n (%)
7 (23)
5 (26)
2 (18)
0.61
Hypertension
23 (77)
14 (74)
9 (82)
0.61
×
×
Conclusion
PCI-CTO success of true CTOs can improve global LV function. The TEI, assessed with CMR, can be used to help predict improvements in regional wall function. Failed PCI was not associated with increased MACE at medium-term follow up.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update Radiologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.